Evidence map›Paper›PMID 35409280›Full record

ArticleInternational journal of molecular sciences2022

Carmen Salguero-Aranda, Amparo Beltran-Povea, Fátima Postigo-Corrales, Ana Belén Hitos, Irene Díaz, Estefanía Caballano-Infantes, Mario F Fraga, Abdelkrim Hmadcha, Franz Martín, Bernat Soria and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Carmen Salguero-ArandaDepartment of Pathology, Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital, CSIC-University of Seville, 41013 Seville, Spain.ORCID 0000-0001-6010-8302
Amparo Beltran-PoveaDepartment of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain.ORCID 0000-0001-6823-8443
Fátima Postigo-CorralesDepartment of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain.ORCID 0000-0002-9457-5088
Ana Belén HitosBiomedical Research Network for Diabetes and Related Metabolic Diseases-CIBERDEM of the Carlos III Health Institute (ISCIII), 08036 Madrid, Spain.ORCID 0000-0002-0403-6647
Irene DíazBiomedical Research Network for Diabetes and Related Metabolic Diseases-CIBERDEM of the Carlos III Health Institute (ISCIII), 08036 Madrid, Spain.
Estefanía Caballano-InfantesDepartment of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain.ORCID 0000-0001-8269-9158
Mario F FragaNanomaterials and Nanotechnology Research Center (CINN-CSIC), Cancer Epigenetics and Nanomedicine Laboratory, 33940 El Entrego, Spain.
Abdelkrim HmadchaDepartment of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain.ORCID 0000-0002-4105-3702
Franz MartínDepartment of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain.
Bernat SoriaBiomedical Research Network for Diabetes and Related Metabolic Diseases-CIBERDEM of the Carlos III Health Institute (ISCIII), 08036 Madrid, Spain.
Rafael Tapia-LimonchiTropical Disease Institute, Universidad Nacional Toribio Rodríguez de Mendoza, Amazonas 01001, Peru.ORCID 0000-0001-7483-1729
Francisco J BedoyaDepartment of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain.ORCID 0000-0003-0262-7029
Juan R TejedoDepartment of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain.ORCID 0000-0002-8434-7516
Gladys M CahuanaDepartment of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain.
Instituto de Salud Carlos III · ESUniversidad Pablo de Olavide · ESCentro Andaluz de Biología Molecular y Medicina Regenerativa · ESNational University Toribio Rodríguez de Mendoza · PEUniversidad de Oviedo · ESUniversitat de Miguel Hernández d'Elx · ESUniversity of Alicante · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transcription factor, early growth response-1 (EGR-1), is involved in the regulation of cell differentiation, proliferation, and apoptosis in response to different stimuli. EGR-1 is described to be involved in pancreatic endoderm differentiation, but the regulatory mechanisms controlling its action are not fully elucidated. Our previous investigation reported that exposure of mouse embryonic stem cells (mESCs) to the chemical nitric oxide (NO) donor diethylenetriamine nitric oxide adduct (DETA-NO) induces the expression of early differentiation genes such as pancreatic and duodenal homeobox 1 (

Indexed as

EndodermMouse Embryonic Stem CellsAnimalsCell DifferentiationEmbryonic Stem CellsMiceNitric OxideNitric OxideEGR-1endoderm differentiationmESCsnitric oxidePdx1

Identifiers

PMID35409280
PMCPMC8999925
OpenAlexW4223443709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.